|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.38 USD | -3.00% |
|
-4.79% | +6.83% |
| 01-15 | Trump Launches Health Care Plan to Reduce Drug Costs | MT |
| 01-12 | Health Care Down on Health-Insurance Concerns -- Health Care Roundup | DJ |
| Capitalization | 22.49B 19.17B 17.76B 16.7B 31.09B 2,047B 33.35B 205B 81B 973B 84.34B 82.61B 3,552B | P/E ratio 2025 * |
-4.53x | P/E ratio 2026 * | 23.3x |
|---|---|---|---|---|---|
| Enterprise value | 25.8B 21.99B 20.38B 19.16B 35.67B 2,348B 38.27B 235B 92.93B 1,117B 96.77B 94.78B 4,075B | EV / Sales 2025 * |
0.13x | EV / Sales 2026 * | 0.13x |
| Free-Float |
79.74% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Centene Corporation
| 1 day | -4.01% | ||
| 1 week | -5.02% | ||
| Current month | +6.56% | ||
| 1 month | +9.76% | ||
| 3 months | +21.47% | ||
| 6 months | +59.86% | ||
| Current year | +6.56% |
| 1 week | 43.28 |  | 47.68 |
| 1 month | 38.58 | | 47.68 |
| Current year | 40.53 | | 47.68 |
| 1 year | 25.08 | | 66.81 |
| 3 years | 25.08 | | 81.42 |
| 5 years | 25.08 | | 98.53 |
| 10 years | 23.68 | | 98.53 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah London
CEO | Chief Executive Officer | 45 | 21/03/2022 |
Drew Asher
DFI | Director of Finance/CFO | 57 | 06/05/2021 |
Susan Smith
COO | Chief Operating Officer | 50 | 31/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 30/03/2023 | |
Jessica Blume
BRD | Director/Board Member | 71 | 04/02/2018 |
H. Dallas
CHM | Chairman | 67 | 22/02/2022 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -0.59% | 1.41% | 26 M€ | |
| 0.00% | 1.31% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.86% | -5.02% | -31.12% | -42.14% | 22.49B | |
| +2.12% | +2.36% | -34.32% | -29.03% | 307B | |
| +0.19% | -1.25% | -5.41% | -22.97% | 81.57B | |
| +1.16% | +0.77% | -5.37% | -11.38% | 72.46B | |
| +0.33% | -1.98% | -5.60% | -45.66% | 32.23B | |
| -1.50% | -1.52% | -37.46% | -37.43% | 9.83B | |
| +0.48% | +4.21% | +55.65% | +84.82% | 4.55B | |
| -0.73% | -2.53% | +18.53% | -24.07% | 2.19B | |
| Average | -0.23% | +1.34% | -5.64% | -15.98% | 66.49B | |
| Weighted average by Cap. | +1.25% | +0.35% | -23.14% | -26.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 193B 164B 152B 143B 267B 17,554B 286B 1,758B 695B 8,347B 723B 708B 30,461B | 193B 165B 152B 143B 267B 17,567B 286B 1,759B 695B 8,353B 724B 709B 30,484B |
| Net income | -4.21B -3.59B -3.32B -3.12B -5.82B -383B -6.24B -38.34B -15.15B -182B -15.77B -15.45B -664B | 883M 752M 697M 656M 1.22B 80.35B 1.31B 8.05B 3.18B 38.21B 3.31B 3.24B 139B |
| Net Debt | 3.31B 2.82B 2.62B 2.46B 4.58B 301B 4.91B 30.19B 11.93B 143B 12.42B 12.17B 523B | 1.87B 1.59B 1.48B 1.39B 2.58B 170B 2.77B 17.03B 6.73B 80.85B 7.01B 6.86B 295B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 44.16 $ | -3.49% | 2,394,514 |
| 20/01/26 | 45.76 $ | +0.02% | 4,253,067 |
| 16/01/26 | 45.75 $ | -3.22% | 7,084,420 |
| 15/01/26 | 47.27 $ | +2.38% | 4,919,516 |
| 14/01/26 | 46.17 $ | +0.90% | 4,546,995 |
Delayed Quote Nyse, January 21, 2026 at 02:47 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CNC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition